Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: A direct comparison study

Journal of Neurochemistry

Volumn 111, Issue 4, 2009, Pages 1042-1050

  Shin, Jin Young ^b   Park, Hyun Jung ^b   Ahn, Young Hwan ^b   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Levodopa; MPTP; Neuroprotection; Parkinson's disease; Pramipexol

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; CYTOCHROME C; DOPAMINE RECEPTOR STIMULATING AGENT; JANUS KINASE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; PRAMIPEXOLE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; BCL-2-ASSOCIATED X PROTEIN; BENZOTHIAZOLES; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GLUTATHIONE; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; NEURONS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 70350134171     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06381.x     Document Type: Article

References (39)

1. Agid Y. (1998) Levodopa: is toxicity a myth? Neurology 50, 858 863.
2. Anderson D. W., Neavin T., Smith J. A. Schneider J. S. (2001) Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res. 905, 44 53.
3. Blunt S. B., Jenner P. Marsden C. D. (1993) Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. 8, 129 133.
4. Canals S., Casarejos M. J., de Bernardo S., Solano R. M. Mena M. A. (2003) Selective and persistent activation of extracellular signal-regulated protein kinase by nitric oxide in glial cells induces neuronal degeneration in glutathione-depleted midbrain cultures. Mol. Cell. Neurosci. 24, 1012 1026.
5. Cavanaugh J. E., Jaumotte J. D., Lakoski J. M. Zigmond M. J. (2006) Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J. Neurosci. Res. 84, 1367 1375.
6. Chen S., Zhang X., Yang D., Du Y., Li L., Li X., Ming M. Le W. (2008) D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 582, 603 610.
7. Cleren C., Vilpoux C., Dourmap N., Bonnet J. J. Costentin J. (1999) Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4- phenylpyridinium or 6-hydroxydopamine in mice. Brain Res. 830, 314 319.
8. Cooper A. J. Kristal B. S. (1997) Multiple roles of glutathione in the central nervous system. Biol Chem 378, 793 802.
9. Datla K. P., Blunt S. B. Dexter D. T. (2001) Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 16, 424 434.
10. De Girolamo L. A. Billett E. E. (2006) Role of extracellular-regulated kinase and c-Jun NH2-terminal kinase in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurofilament phosphorylation. J. Neurosci. Res. 83, 680 693.
11. Dhanasekaran D. N. Reddy E. P. (2008) JNK signaling in apoptosis. Oncogene 27, 6245 6251.
12. Du F., Li R., Huang Y., Li X. Le W. (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 22, 2422 2430.
13. Emborg M. E. (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139, 121 143.
14. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C. W., Tanner C. Marek K. (2004) Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498 2508.
15. Gu M., Iravani M. M., Cooper J. M., King D., Jenner P. Schapira A. H. (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075 1081.
16. Han S. K., Mytilineou C. Cohen G. (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66, 501 510.
17. Iida M., Miyazaki I., Tanaka K., Kabuto H., Iwata-Ichikawa E. Ogawa N. (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838, 51 59.
18. Iravani M. M., Haddon C. O., Cooper J. M., Jenner P. Schapira A. H. (2006) Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96, 1315 1321.
19. Jones D. P., Carlson J. L., Samiec P. S., Sternberg P. Jr., Mody V. C. Jr., Reed R. L. Brown L. A. (1998) Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin. Chim. Acta 275, 175 184.
20. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y. Taniguchi T. (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59 67.
21. Karunakaran S., Saeed U., Mishra M., Valli R. K., Joshi S. D., Meka D. P., Seth P. Ravindranath V. (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J. Neurosci. 28, 12500 12509.
22. Kirik D., Rosenblad C. Bjorklund A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259 277.
23. Kulich S. M. Chu C. T. (2001) Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 77, 1058 1066.
24. Le W. D., Jankovic J., Xie W. Appel S. H. (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 107, 1165 1173.
25. Melamed E., Offen D., Shirvan A., Djaldetti R., Barzilai A. Ziv I. (1998) Levodopa toxicity and apoptosis. Ann. Neurol. 44, S149 S154.
26. Mena M. A., Davila V. Sulzer D. (1997) Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J. Neurochem. 69, 1398 1408.
27. Mena M. A., Davila V., Bogaluvsky J. Sulzer D. (1998) A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol. Pharmacol. 54, 678 686.
28. Miloso M., Scuteri A., Foudah D. Tredici G. (2008) MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr. Med. Chem. 15, 538 548.
29. Murer M. G., Dziewczapolski G., Menalled L. B., Garcia M. C., Agid Y., Gershanik O. Raisman-Vozari R. (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43, 561 575.
30. Mytilineou C., Walker R. H., JnoBaptiste R. Olanow C. W. (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304, 792 800.
31. Olanow C. W., Kieburtz K. Schapira A. H. (2008) Why have we failed to achieve neuroprotection in Parkinson's disease? Ann. Neurol. 64 (Suppl 2 S101 S110.
32. Peng J. Andersen J. K. (2003) The role of c-Jun N-terminal kinase (JNK) in Parkinson's disease. IUBMB Life 55, 267 271.
33. Saporito M. S., Thomas B. A. Scott R. W. (2000) MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75, 1200 1208.
34. Schapira A. H., Gu M., Taanman J. W., Tabrizi S. J., Seaton T., Cleeter M. Cooper J. M. (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44, S89 S98.
35. Schober A. (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318, 215 224.
36. Spencer J. P., Jenner P. Halliwell B. (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 6, 1480 1484.
37. Vila M., Ramonet D. Perier C. (2008) Mitochondrial alterations in Parkinson's disease: new clues. J. Neurochem. 107, 317 328.
38. West M. J., Slomianka L. Gundersen H. J. (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482 497.
39. Zigmond M. J. (2006) Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model. J. Neural Transm. Suppl. 70, 439 442.